EP3423045A1 — Pharmaceutical compositions for on demand anticoagulant therapy
Assigned to Kenox Pharmaceuticals Inc · Expires 2019-01-09 · 7y expired
What this patent protects
A pharmaceutical composition for adminstration of Dabigatran etexilate through the mucous membranes of the oral cavity, characterized in that the composition comprises a therapeutically effective amount of Dabigatran etexilate and a solubilizer for Dabigatran etixilate selected f…
USPTO Abstract
A pharmaceutical composition for adminstration of Dabigatran etexilate through the mucous membranes of the oral cavity, characterized in that the composition comprises a therapeutically effective amount of Dabigatran etexilate and a solubilizer for Dabigatran etixilate selected from at least one of a water soluble derivative of tocopherol and a polymeric derivative of sorbitan. The composition may be in the form of solid oral film. The composition may be suitable for dropwise administration. A method of manufacturing the film composition is also included.
Drugs covered by this patent
- Celebrex (celecoxib) · Pfizer Inc. (originally Searle/Pharmacia)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.